First and Only Parp Inhibitor, Lynparza® (Olaparib) Approved as a First-line Maintenance Therapy Treatment in BRCA-Mutated Advanced Ovarian Cancer

_______________________________

_ⁱ AstraZeneca Canada Inc., Lynparza® (olaparib) tablets. Product Monograph. May 2019.

ⁱⁱ Ibid.

ⁱⁱⁱ Ibid.

^_iv Ibid.

^v Ibid.

^vi Ibid.

^vii Ovarian Cancer Canada. About Ovarian Cancer. Accessed April 10, 2019. Available at: http://www.ovariancanada.org/about-ovarian-cancer

^viii Canadian Cancer Society. Ovarian Cancer Statistics. Accessed April 10, 2019. Available at: http://www.cancer.ca/en/cancer-information/cancer-type/ovarian/statistics/?region=on

^ix Ovarian Cancer Canada. About Ovarian Cancer. Disease Basics. Accessed April 10, 2019. Available at: https://ovariancanada.org/About-Ovarian-Cancer/Disease-Basics/What-is-ovarian-cancer